AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30939489
Drug: EBR 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBR 50 mg plus GZR 100 mg once daily for 12 weeks (control group)
Trial: 30940770
Drug: Prednisolone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.5 mg/kg for 7 days)
Trial: 30940999
Drug: Tdap (tetanus
RxNorm normalized name: Adacel Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine
Trial: 30941094
Drug: Apomorphine, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine, dosage and duration not available
Trial: 30941095
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP) intramuscular injections
Trial: 30942111
Drug: Drug adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug adherence assessment via toxicological urine analysis
Trial: 30943124
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision.
Trial: 30943782
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of shoes equipped with the foot compression device (Footbeat™, AVEX, Grand Junction, CO, USA) for 4 weeks
Trial: 30943913
Drug: Serum klotho
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum klotho levels < 518 pg/mL
Trial: 30943928
Drug: Circulating tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating tumor cell (CTC) detection before therapy and after one course of preoperative FOLFOX
Trial: 30946917
Drug: Newborn SCID
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newborn SCID screening using quantification of T-cell receptor excision circles (TRECs) on Guthrie cards
Trial: 30949435
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) in a waiting list control group (WLC)
Trial: 30949674
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals treatment
Trial: 30950636
Drug: Pirfenidone treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone treatment, timing of treatment initiation not specified.
Trial: 30951840
Drug: One-time infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time infusion of donor-derived cytokine-induced killer (CIK) cells at a dose of 1 × 10^6 cells/kg.
Trial: 30952529
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular hypertrophy (LVH) identified by LV mass index >46.7 g/m
Trial: 30952619
Drug: Loss-of-function mutations
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loss-of-function mutations in epigenetic modulator genes (47%)
Trial: 30952619
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor (AR) gene alterations (7%)
Trial: 30953238
Drug: Afatinib (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (20, 30, 40, or 50 mg/day; physician decision)
Trial: 30954717
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (chemotherapy with ifosfamide/doxorubicin)
Trial: 30954717
Drug: Intermediate-/high-risk therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-/high-risk therapy (chemotherapy ± surgery ± radiotherapy)
Trial: 30955188
Drug: Evocalcet 1-8
RxNorm normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Evocalcet 1-8 mg orally once daily for 32 weeks
Trial: 30955420
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg cannabidiol
Trial: 30955420
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg cannabidiol
Trial: 30956800
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone application for daily breathlessness rating (0-10 NRS)
Trial: 30956800
Drug: Daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily and weekly recall of breathlessness
Trial: 30956961
Drug: Gum arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum arabic (GA) 30 g/day for 12 weeks
Trial: 30957229
Drug: Reinduction chemotherapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinduction chemotherapy plus bortezomib
Trial: 30958020
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy (ICBT) course (8-week guided)
Trial: 30958892
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off combined with intravenous cetuximab 250 mg/m²
Trial: 30958892
Drug: Various dose
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various dose levels of regorafenib administered QD continuously or intermittently (3 weeks on/1 week off)
Trial: 30959163
Drug: Pembrolizumab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (9 doses, i.v., 1 dose every 21 days starting on day +14 post-AHCT)
Trial: 30959477
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2800 IE daily)
Trial: 30962120
Drug: Low-sugar diet
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sugar diet (added sugars comprised 2.5% to 4.0% of daily calories)
Trial: 30962222
Drug: SIRPαFc (TTI-621),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIRPαFc (TTI-621), a novel CD47 decoy receptor, administered in clinical trial settings.
Trial: 30962233
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment practices for PDN according to guidelines and local practices
Trial: 30962330
Drug: Isavuconazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (single oral dose of isavuconazonium sulfate)
Trial: 30962334
Drug: Imipenem-cilastatin (IMP-CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (IMP-CS) at 15 mg/kg every 6 hours
Trial: 30962334
Drug: Imipenem-cilastatin (IMP-CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (IMP-CS) at 20 mg/kg every 6 hours
Trial: 30962334
Drug: Imipenem-cilastatin (IMP-CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (IMP-CS) at 25 mg/kg every 6 hours
Trial: 30962681
Drug: Aclidinium bromide/formoterol
RxNorm normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg
Trial: 30962681
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) 18 µg
Trial: 30962681
Drug: Aclidinium (AB)
DrugBank: Aclidinium (DB08897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium (AB) 400 µg
Trial: 30962681
Drug: Formoterol (FF)
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol (FF) 12 µg
Trial: 30962697
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U100 plus insulin aspart
Trial: 30962729
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg once daily)
Trial: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 10 mg/m2/day
Trial: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 15 mg/m2/day
Trial: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 20 mg/m2/day
Trial: 30962963
Drug: Decitabine (5-aza-2'-deoxycytidine)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion
Trial: 30963179
Drug: Feminizing hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feminizing hormone therapy (FHT)
Trial: 30963212
Drug: Neoadjuvant nab-PTX
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nab-PTX 260 mg/m2 with trastuzumab every 3 weeks for four cycles
Trial: 30963506
Drug: Erenumab (140-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (140-mg subcutaneous dose)
Trial: 30963506
Drug: Norgestimate/ethinyl estradiol-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate/ethinyl estradiol-containing oral contraceptive
Trial: 30963691
Drug: Galunisertib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib (80 or 150 mg BID for 14 days per 28-day cycle)
Trial: 30964436
Drug: e-message intervention
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-message intervention (3 to 4 electronic weekly messages)
Trial: 30964439
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention consisting of monthly telephone calls for 6 months by a case manager and weekly, one-way informational text messages.
Trial: 30964819
Drug: Anti-Saccharomyces cerevisiae
RxNorm normalized name: Anti-Saccharomyces cerevisiae IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Saccharomyces cerevisiae mannan antibodies (ASCA)
Trial: 30964819
Drug: Antineutrophil cytoplasmic
RxNorm normalized name: c-Antineutrophil cytoplasmic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineutrophil cytoplasmic antibodies
Trial: 30965011
Drug: Double-Dose Alpha-1
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-Dose Alpha-1 Antitrypsin Augmentation Therapy
Trial: 30968255
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training combined with chemotherapy
Trial: 30968301
Drug: Antiplatelet agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agent cangrelor
Trial: 30968368
Drug: Lopinavir/Ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir monotherapy
Trial: 30968368
Drug: Combination antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir
Trial: 30969486
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle intervention programme with whey supplements (30 g/day) and personalized resistance training regimen for 32 elderly subjects from the sarcopenic cohort.
Trial: 30969486
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of TNF-α (>11.15 pg/mL) and TWEAK (>1276.48 pg/mL) in sarcopenic patients.
Trial: 30969486
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of serum levels of proinflammatory cytokines and metabolic hormones between sarcopenic and non-sarcopenic subjects.
Trial: 30971261
Drug: EQ-5D-5 L
RxNorm normalized name: Anthelcide EQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ-5D-5 L
Trial: 30972619
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (n=919)
Trial: 30973373
Drug: Alisertib 20
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 20 mg twice daily and Pazopanib 600 mg daily (DL 2)
Trial: 30975203
Drug: Iron status
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron status assessment using plasma ferritin and soluble transferrin receptor (sTfR) measurements.
Trial: 30975630
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m²), fluorouracil, and vincristine, administered in two 21-day cycles within 42 days of resection.
Trial: 30975630
Drug: Cisplatin, fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, fluorouracil, and vincristine (adjuvant chemotherapy).
Trial: 30976780
Drug: Inflammation defined
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammation defined as CRP >5 mg/L or AGP >1 g/L, or both
Trial: 30976898
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy using esophageal Doppler monitoring (EDM) during laparoscopic adrenalectomy for PCC patients.
Trial: 30976898
Drug: PCC patients
RxNorm normalized name: PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCC patients receiving goal-directed fluid therapy using EDM.
Trial: 30978536
Drug: Bismuth salts
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth salts (240 mg) combined with proton pump inhibitors (esomeprazole, omeprazole, pantoprazole, rabeprazole), amoxicillin (1 g), and clarithromycin (500 mg), all taken twice daily for 14 days.
Trial: 30978536
Drug: Bismuth salts
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth salts (240 mg) combined with standard triple therapy.
Trial: 30978536
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy without bismuth (not explicitly mentioned in the abstract).
Trial: 30978536
Drug: Bismuth salts
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth salts with a double dose of proton pump inhibitor (equivalent to 40 mg omeprazole).
Trial: 30978536
Drug: 14-day duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day duration of treatment.
Trial: 30978536
Drug: Treatment compliance.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment compliance.
Trial: 30979361
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment plan [multiple choice]
Trial: 30979811
Drug: Low birth
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low birth weight (LBW) (<2500 g)
Trial: 30980576
Drug: ombitasvir/paritaprevir/ritonavir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ombitasvir/paritaprevir/ritonavir + dasabuvir with low-dose ribavirin for 12 weeks
Trial: 30980734
Drug: Fostemsavir (FTR)
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir (FTR) 600 mg twice daily
Trial: 30980827
Drug: Etonogestrel contraceptive
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etonogestrel contraceptive implants
Trial: 30981783
Drug: Lentiviral vector-derived
RxNorm normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentiviral vector-derived gene therapy
Trial: 30981987
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ctDNA, patient age, and serum biomarkers
Trial: 31253622
Drug: Rectal screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal screening
Trial: 30982000
Drug: Rectal site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal site testing
Trial: 30982564
Drug: Intraoperative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative low-dose fentanyl (about 60-120 μg for a 70 kg patient)
Trial: 30982564
Drug: High intraoperative
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intraoperative fentanyl doses (median: 3.85; IQR: 3.42-4.50 μg kg)
Trial: 30984354
Drug: Daily walnut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily walnut intake (45 g for 16 weeks)
Trial: 30985279
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost treatment via the Breelib nebulizer for 3 months ± 2 weeks, in addition to existing PAH therapy.
Trial: 30985279
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost treatment via the Breelib nebulizer.
Trial: 30985369
Drug: Autologous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fat transfer (AFT); average volume: 23.9 ± 13.2 mL
Trial: 30986523
Drug: Inappropriate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate empirical antibiotic therapy (IEAT)
Trial: 30986523
Drug: Inappropriate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate empirical antibiotic therapy (IEAT) in bloodstream infections
Trial: 30986735
Drug: Mood stabilizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood stabilizing anticonvulsants (MSAs)
Trial: 30986735
Drug: Polypharmacy (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (combination of drugs)
Trial: 30986750
Drug: Moderate doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate doses of statins at discharge
Trial: 30987597
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml albumin 5% administered over 1 min in three consecutive 50-ml fluid boluses, followed by an additional 350 ml infused at a constant rate over 15 min (total 500 ml)
Trial: 30988080
Drug: High-dose lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lapatinib (1,500 mg BID)
Trial: 30988080
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose lapatinib alternating with capecitabine
Trial: 30989436
Drug: Various anti-glioblastoma
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various anti-glioblastoma agents including temozolomide, carmustine, lomustine, procarbazine, irinotecan, cediranib, erlotinib, 5-fluorouracil, vincristine, dichloroacetate, IDH1 inhibitor ivosidenib; treatment duration: 3 or 6 days
Trial: 30990523
Drug: 10% IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% IV infusion of glucose during exercise
Trial: 30991823
Drug: Adaptive Cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive Cardiac Resynchronization Therapy
Trial: 30991992
Drug: Micafungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (50 mg intravenously once daily during first induction chemotherapy)
Trial: 30994466
Drug: Dignity Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity Therapy (DT) led by nurses or chaplains
Trial: 30994825
Drug: Dual anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual anti-platelet therapy (DAPT)
Trial: 30995146
Drug: Anti-clot treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-clot treatment scale
Trial: 30995146
Drug: Treatment satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment satisfaction questionnaire for medication version II
Trial: 30995208
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg·kg infused over 1 hour, repeated every 12 hours
Trial: 30995208
Drug: Cefazolin 30
RxNorm normalized name: cefazolin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 30 mg·kg infused over 10 minutes, repeated every 4 hours
Trial: 30995372
Drug: Lentiviral vector
RxNorm normalized name: Lentiviral Vector Expressing Human Fumarylacetoacetate Hydrolase
DrugBank: LV-FAH (DB17686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentiviral vector gene therapy combined with low-dose busulfan conditioning
Trial: 30995373
Drug: UB-421 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UB-421 (10 mg/kg weekly)